The Food and Drug Administration has been on a march to collect cannabinoid-related data. The “Cannabis-Derived Products Data Acceleration Plan” released this month is its most robust effort.
Epidiolex strikes again: the FDA-approved CBD-based pharmaceutical is complicating other uses of CBD.
CSU Pueblo hosted a pharmacist at Greenwich Biosciences to talk about the company’s path with Epidiolex, a CBD-based medicine extracted from cannabis plants.
The group, which includes Coca-Cola and Kellogg’s as members, says its membership is “CBD curious” but that the lack of federal regulation is keeping major brands at bay.
“I’m getting very hopeful that we're headed down the road to seeing some hemp-derived ingredients approved for use in animal food,” said the FDA’s Deputy Director in the Division of Animal Feeds.
The FDA, which has been crafting rules for CBD products since 2019, says it is seeking partnerships, from academia to government and the cannabis industry, to “develop the foundation for more robust CBD data collection.”
The Food and Drug Law Institute is hosting officials from several federal agencies this week to discuss cannabis policies.
One company is focused on the future of CBD in supplements. The other, on its future in pharmaceuticals.
During a recent webinar, the FDA detailed how its Drug Master Files process could speed up research, while keeping proprietary information secret.
Among the new names on the list of entities seeking to discuss the FDA’s forthcoming rules on CBD products: American Bankers Association and Columbia Care.
Epidiolex contains cannabidiol, or CBD, extracted from cannabis plants, and was first approved to treat severe forms of epilepsy.
The Food and Drug Administration drafted its long-awaited CBD policy, and sent it to the White House Office of Management and Budget for approval, a final step before publication.
The US Department of Transportation committee heard a presentation and asked questions about how the passage of the 2018 Farm Bill, and proliferation of CBD, is affecting the nation’s commercial drivers.
Consumer Brands Association, which counts among its members Kellogg’s, Coca-Cola Company, and PepsiCo, Inc., brought together a diverse group to focus on federal CBD policies.
Figi’s story raised awareness about the potential for CBD to reduce seizures, and led to CBD legislation and research around the world.
The DEA has taken Epidiolex, a CBD-based formula for rare forms of epilepsy, completely off its list of controlled substances. Why? The 2018 Farm Bill.